The latest reimbursement price listing of generic drugs in Japan includes nine active ingredients opened up to such competition for the first time, including Kyowa Hakko Kirin's and Dainippon Sumitomo Pharma's (DSP) number two products and others from AstraZeneca and Astellas.
The latest reimbursement price listing of generic drugs in Japan includes nine active ingredients opened up to such competition for the first time, including Kyowa Hakko Kirin's and Dainippon Sumitomo Pharma's (DSP) number two products and others from AstraZeneca and Astellas.
In all, 595 preparations from 63 firms were included in the reimbursement tariff (which allows launch) on 14 December, in...
Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.
After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.
Swiss major confident that new oncology drugs will fill revenue gap.
